Pfizer (NYSE:PFE) Shares Up 1.3%

Shares of Pfizer Inc. (NYSE:PFE) traded up 1.3% on Wednesday . The stock traded as high as $28.19 and last traded at $28.08. 6,433,880 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 39,865,332 shares. The stock had previously closed at $27.72.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday. Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $35.54.

Pfizer Trading Up 1.7 %

The firm has a market capitalization of $159.68 billion, a P/E ratio of -469.59, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The firm has a 50 day moving average price of $28.18 and a two-hundred day moving average price of $27.71.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.23 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a dividend yield of 5.96%. Pfizer’s dividend payout ratio is -2,799.53%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently bought and sold shares of PFE. Olistico Wealth LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $25,000. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $32,000. Trivant Custom Portfolio Group LLC grew its position in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Finally, VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.